|1.||Cuzzocrea, Salvatore: 46 articles (10/2012 - 02/2003)|
|2.||Hazen, Stanley L: 42 articles (09/2015 - 11/2002)|
|3.||Mazzon, Emanuela: 41 articles (11/2011 - 02/2003)|
|4.||Di Paola, Rosanna: 35 articles (10/2012 - 02/2003)|
|5.||Genovese, Tiziana: 30 articles (02/2010 - 09/2003)|
|6.||Sener, Göksel: 27 articles (05/2014 - 06/2002)|
|7.||Suzuki, Kazuo: 26 articles (06/2014 - 01/2002)|
|8.||Heinecke, Jay W: 25 articles (01/2016 - 01/2002)|
|9.||Heeringa, Peter: 22 articles (12/2013 - 10/2002)|
|10.||Muià, Carmelo: 22 articles (08/2008 - 02/2005)|
02/01/2014 - "DSS-induced colitis clearly induced Myeloperoxidase activity in the colon, which was significantly reduced by treatments with 3% DSS-pGLP-2 or 3% DSS-PEG-pGLP-2. These results showed that site-specific Lys(30)-PEG-GLP-2 was resistant to degradation and reduced the severity of colonic injury in murine colitis. "
01/01/2007 - "Both probiotics showed intestinal anti-inflammatory effects in this model of experimental colitis, as evidenced histologically and by a significant reduction of colonic myeloperoxidase activity (P<0.05). "
02/01/2006 - "Histologic scores of colonic damage and myeloperoxidase activity were lower in both probiotic-treated groups compared with those of the colitis control group (P<0.001), although the mentioned scores improved significantly more in the high-EPS group than in the low-EPS group (P<0.001). "
05/28/2014 - "The results indicated that the dietary incorporation of Salecan attenuated the severity of DSS colitis as evidenced by the decreased disease activity index, reduced severity of anaemia, attenuated changes in colon architecture and reduced colonic myeloperoxidase activity. "
03/01/2011 - "The macroscopical and histological scoring systems, wet colon mass index and myeloperoxidase activity were assessed to evaluate the efficacy of the capsule after administered orally to experimental colitis mice. "
01/24/2014 - "In a chronic skin inflammation model, a marked reduction in ear thickness, associated with significant reduction in myeloperoxidase accumulation, was observed. "
11/01/2015 - "The murine model of TRALI was successfully established as evidenced by pulmonary oedema, accompanied by decreased clearance of bronchoalveolar lavage fluid (BALF), increased pulmonary and systemic inflammation, elevated lung myeloperoxidase (MPO) activity as well as increased pulmonary and systemic coagulation in the TRALI group compared with those in the control group. "
12/01/2013 - "The reduction in local inflammation from the two-week course of VSL#3 is correlated to a significant reduction in levels of active IL-1β, and tissue levels of myeloperoxidase. "
02/15/2013 - "Additionally, inflammation of the colon determined by the number of myeloperoxidase-positive cells and colonic transit time were significantly improved in aly/aly mice, FTY720-treated wild-type mice, and in MLN ex mice. "
05/01/2015 - "In vivo studies showed that F15 achieved significant decrease in myeloperoxidase activity and inflammation with delayed Tmax (4 h) and lower Cmax (2700 ng/ml) when compared to marketed product."
01/01/2015 - "The extract showed anti-inflammatory activity in the ear edema in mice test (34.3% inhibition), myeloperoxidase (MPO) activity was markedly reduced in animals administered with the extract: within 49.6% and 68.5%. "
11/18/2014 - "BBL was characterized, and its supplementation in situ led to significant decrease in paw edema, tissue myeloperoxidase activity, NO level, serum TNFα level and CINC 1 level as well as decrease in splenic CD4(+)/CD8(+) ratios and increase in level of Treg cells. "
07/01/2014 - "Paw diameter and tissue myeloperoxidase activity in the paws were evaluated as indices for edema and neutrophil infiltration into the tissue. "
06/27/2014 - "The anti-inflammatory activity of compounds 1-5 was determined using the 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced ear edema model, and the effect of compounds 1-4 on the recruitment of neutrophils was evaluated using the myeloperoxidase test. "
01/01/2014 - "Lethality rate, blood gas, myeloperoxidase (MPO) activity, lung edema and pathological changes were used to evaluate the degree of ALI. "
04/01/2015 - "Markers of lung injury including permeability index, myeloperoxidase content, and bronchoalveolar lavage inflammatory cell counts were all reduced with toll-like receptor-4 knockdown. "
05/01/2014 - "Furthermore, compared with MSCs treated alone, Del1-MSC-treated mice also exhibited low lung injury scores, high protein concentrations and myeloperoxidase activity. "
02/01/2014 - "Lung injury was assessed by the histopathological changes, arterial blood gas, wet/dry (w/d) weight ratio and myeloperoxidase (MPO) activity of the lung. "
01/01/2014 - "Lung injury was evaluated via histology and lung neutrophil infiltration was evaluated by myeloperoxidase (MPO) staining. "
06/01/2012 - "Lung injury was assessed by wet/dry ratio, myeloperoxidase (MPO) activity, and bronchoalveolar lavage (BAL) neutrophil counts. "
|5.||Body Weight (Weight, Body)
08/01/2006 - "Both Cur and Dex improved body weight loss, ameliorated histological images and decreased macroscopic score and myeloperoxidase activity. "
05/01/2013 - "Changes of body weight, survival rate, myeloperoxidase (MPO) activity were monitored and macroscopic and microscopic injury scores are calculated. "
01/30/2013 - "The mice body weight, colonic wet weight, colonic lengths, myeloperoxidase (MPO) activity, macroscopic and histological colon injury were observed. "
04/01/2012 - "Body weight and colon length significantly decreased and the disease activity index score, histologic score, and myeloperoxidase activity significantly increased in HNP-1-treated BALB/c mice compared with PBS-treated mice. "
01/17/2012 - "Colon/body weight ratio, myeloperoxidase activity and histological evaluation were performed. "
|1.||Antineutrophil Cytoplasmic Antibodies (ANCA)
|2.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|6.||Glutathione (Reduced Glutathione)
|7.||Myeloblastin (Proteinase 3)
|9.||Evans Blue (Blue, Evans)
|4.||Drug Therapy (Chemotherapy)